Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where Is OxyContin Abuse Deterrent Data? Purdue Has Sent Two Studies, But Wait Continues

Executive Summary

US FDA expects to receive two more postmarket studies this year, but Purdue has not yet decided if it will resubmit a supplemental NDA. Consortium of 13 companies have completed six additional studies on extended-release opioids.

Advertisement

Related Content

Deal Watch: Purdue Continues Move Away From Opioids With Alivio Deal
US FDA’s Most Unusual Advisory Committee
Mallinckrodt's Abuse Deterrent Oxycodone IR Narrowly Wins US FDA Panel Backing
Purdue's Pain And No Gain: More Analysis Of OxyContin Postmarket Studies Needed
Purdue's reformulated OxyContin gets US panel backing on second try

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel